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INTRODUCTION 
CONSIDERABLE indirect evidence, associating serotonin with central nervous system function 
and the actions of important psychotropic drugs, led to suggestions192 of a relationship 
between serotonin metabolism and schizophrenia. Despite considerable effort, experimental 
support for this suggestion has been inconclusive. Among studies in this area are those on 
quantitative excretion, and variability of excretion, of serotonin’s major metabolite, 5- 
hydroxyindoleacetic acid, by various diagnostic populations, and on the relationship 
between such excretion and clinical symptomatology. Thus, schizophrenics have been 
reported variously to excrete supernormal,a-5 subnormal,6 and normal”3 amounts of this 
metabolite, and to show excessive variability in excretion. More recently a direct relationship 
between urinary levels of 5-hydroxyindoleacetic acid and other tryptophan metabolites 
and clinical symptomatology has been reported.rs-1s 
As part of a larger multidisciplinary study on the attributes of schizophrenia,? it was 
possible to examine some of these reports on a large population maintained under con- 
trolled conditions.ls~sO The present paper deals with a comparison of the quantitative 
excretion of 5-hydroxyindoleacetic acid by various diagnostic populations, and an analysis 
of the correlations between such excretion and pertinent biological and behavioral variables. 
* Present address: Neurobiochemistry Laboratory, Veterans Administration Center, Wilshire and 
Sawtelle Boulevards, Los Angeles, California 90073. 
t This investigation was carried out as part of the Schizophrenia and Psychopharmacology Joint Research 
Project, supported by USPHS MY-1972, MY-4567 and MH-O7293-01. The author is indebted to Mr. T. 
Best for technical assistance, Mr. N. Mattsson for statistical help, and Drs. R. W. Gerard, S. Gershon 
and E. Geller for their helpful comments. 
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MATERIALS AND METHODS 
Subjects. Schizophrenic and nonschizophrenic subjects 18-50 years of age were drawn from 
the male population of Ypsilanti State Hospital. Admission to the research ward was 
contingent upon unanimous concordance on primary diagnosis (obtained independently 
by three psychiatrists) and the absence of concurrent physical illnesses. All psychiatrists 
had access to the medical records. 
Diagnostic subdivisions into paranoid schizophrenic, non paranoid schizophrenic, non- 
schizophrenic with chronic brain syndrome, and nonschizophrenic without chronic brain 
syndrome were established by the majority judgment of the three psychiatrists on the 
predominant psychiatric and medical state of the subjects. While unanimity was not required, 
it was achieved in the majority of cases. 123 subjects (63 schizophrenics and 60 nonschizo- 
phrenics) were admitted to the research ward in diagnostically mixed groups of five. 
Medication was terminated two months before testing, and subjects were maintained on an 
unvarying diet with daily vitamin supplementation throughout their stay on the research 
ward. A three-week period of dietary adjustment was allowed. Baseline biochemical 
determinations were made during the fourth week when diet was rigidly controlled and ward 
observation carried out. Specimens were discarded from subjects failing to consume their 
diet completely. The mean age of the schizophrenics in this study was 35.8 f 8.25” years, 
and they had been hospitalized for 544 f 77.4 months. Psychiatric and ward ratings were 
carried out using Lorr MSRPP2r and the Gorham Ward Rating Scale.22 
Specimens. Urines were collected over 24-hour p,eriods and were refrigerated at 5°C 
between collections. Analytical determinations were carried out daily. Estimations of 
5-hydroxyindoleacetic acid were not carried out on samples having a pH greater than 6.9. 
Methods. Urinary 5-hydroxyindoleacetic acid was estimated by the procedure of UDEN- 
FRIEND et aZ.,23 creatinine by a Jaffe reactions4 and sodium by flame photometry. In most 
instances individual figures for 5-hydroxyindoleacetic acid and sodium are the average of 
two samples taken two days apart, while figures for total volume and urinary creatinine 
are the means for five determinations. Reported values, therefore, are the means of such 
individual averages. Cross- and intra-correlations were computed from daily individual 
24-hour values, rather than pooled mean values, and the variables in question. 
RESULTS AND DISCUSSION 
Comparisons of the 5-hydroxyindoleacetic acid excretion by various diagnostic popula- 
tions (Table 1) substantiate those investigations?14 concluding that schizophrenics and 
nonschizophrenics do not differ in 5-hydroxyindoleacetic acid excretions. Non paranoid 
schizophrenics did differ significantly (P <0.05) from both paranoid schizophrenics and 
nonschizophrenics with chronic brain syndrome in the urinary concentration of 5-hydroxy- 
indoleacetic acid but not in total daily excretion. However, of the 30 cross comparisons 
* Mean f standard deviation. 
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TABLE 1. MEAN EXCRETION OF 5-HY~ROXYINDOLEA~ETI~ ACID BY VARIOUS DIAGNOSTIC 
POPULATIONS 
N Mean S.D. Mean SD. 
cL8iml p8/ml mg/24h mg/24h 
Schizophrenics 63 4.47 2.58 4.46 2.35 
Paranoid 22 3.86 1.70* 5.28 2.62 
Nonparanoid 41 4.79 2.92* 4.02 2.08 
Nonschizophrenics 60 4.36 2.34 5.06 2.76 
CBS? 22 4.65 259” 5.54 3.49 
Non CBS 38 4.23 2.26 4.69 2.27 
* Nonparanoid schizophrenics differ from paranoid schizophrenics P ~0.05, 
and from nonschizophrenics with chronic brain syndrome P <0.05. 
f Nonschizophrenics with chronic brain syndrome. 
TABLE 2. RELATIONSHIP BETWEEN SELECTED PSYCHIATRIC FACTORS ANJJ 24 h 5-HyOROXnNDOLEACETIC 
ACID EXCRETION BY SCHIZOPHRENICS 
Psychiatric item definition N Y* PI- PS S--N@ 
Lorr A-Depression vs excitement 
Lorr B-Compliance vs resistiveness 
Lorr C-Paranoid projection 
Lorr D-Activity (under vs over) 
Lorr E-Melancholy agitation 
Lorr F-Perceptual distortion 
Lorr G-Motor disturbance 
Lorr H-Submissive vs belligerent 
Lorr I-Withdrawal (more vs less) 
Lorr J- Self depreciation vs gran- 
doise expansion 
Lorr K-Conceptual disorganization 
Gorham l-Activity level 
Gorham 2-Anxiety level 
Gorham 3-Mental disorganization 
Gorham &-Mood (depressed vs 
euphoric) 
Gorham S-Interpersonal relations 
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* Pearson correlation coefficient. 
t Probability of the correlation; NS signifies not significant. 
$ Distinguish between schizophrenics and nonschizophrenics at the indicated probability level. 
0 + Mean for schizophrenics greater than mean for nonschizophreuics. 
- Mean for schizophrenics less than mean for nonschizophrenics. 
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between schizophrenics, nonschizophrenics, and their various sub-populations in this 
analysis, one and one-half differences of the 0.05 level would be expected by chance alone, 
and it is unlikely that the two statistical differences observed had clinical significance. 
It is also of interest that the variance was nearly identical for schizophrenics and non- 
schizophrenics; and ranges of individual values for 24-hour excretion was also comparable 
between these groups. The extreme values for schizophrenics ranged from 1.09 mg/24 h 
(a non paranoid schizophrenic) to 12.79 mg/24 h (a paranoid schizophrenic) while the 
extremes among nonschizophrenics were 1 *l 1 mg/24 h to 11.69 mg/24 h (two nonschizo- 
phrenics without chronic brain syndrome). Thus, it would appear that schizophrenics do not 
show greater variability than nonschizophrenics on this measure when both are maintained 
under similar environmental conditions. 
It has been suggestedI’ that ‘exacerbations of schizophrenic activity in terms of aggrava- 
tions of hallucinatory and delusional experiences as well as agressiveness and hostility’ 
are accompanied by increased urinary excretion of tryptamine, indole-3-acetic acid, and 
5-hydroxyindoleacetic acid. Correlations between 5-hydroxyindoleacetic acid excretion and 
various pertinent behavioral and biological variables were analyzed, therefore, to assess 
the validity of the postulated relationship for this compound. The correlations between 
metabolite excretion and LORR~~ and GORHAM~~ rating factors, presented in Table 2, not 
only fail to support this suggested relationship, but even suggest the opposite trend, of 
decreasing psychopathology with increasing 5-hydroxyindoleacetic acid excretion. Excre- 
tion of 5-hydroxyindoleacetic acid correlated significantly with withdrawal on both the 
Gorham 5 and Lorr I in the direction of less withdrawal with higher excretion, and with 
the Mental Disorganization Factor, Gorham 3, in the direction of less mental disorganiza- 
tion with higher excretion. Correlations with other rating factors failed to reach statistical 
significance, but, with the exception of the Lorr A, all were in the direction of decreased 
schizophrenic psychopathology with increased 5-hydroxyindoleacetic acid excretion. The 
Lorr I and the Gorham 5 in this study correlated remarkably well for these types of measures 
(r = O-764, P = 0.001, N = 99) so that both factors seem to be estimating similar pheno- 
mena. Although single rating factors may not fully reflect global pathology, 15 of the 17 
Lorr and Gorham scale items distinguished schizophrenics from nonschizophrenics in this 
study and 10 did so at P <O.OOl. 
Because of the difficulty in specifying clinical state and environmental conditions precisely 
it is conceivable that the negative relationship between 5-hydroxyindoleacetic acid and 
psychopathology observed in this cross-sectional study and the positive relationship 
reported in longitudinal studies may reflect extraneous influences on 5-hydroxyindoleacetic 
acid excretion. For example, the nine schizophrenic subjects studies by BERLET et a1.l’ 
ranged in age from 39-59 years (mean 53) and were hospitalized for from 6-28 years (mean 
19). The schizophrenics in our study were younger (35.8 f 8.2 years of age) and had been 
hospitalized for a lesser period (4.53 f 6.45 years). However, in our study, hospitalization 
(but not age) correlated negatively with 5-hydroxyindoleacetic acid excretion (r = -0.38 1; 
P cO.Ol), so that neither experimental difference alone appears to account for the differences 
in the findings. As expected, hospitalization and, to a lesser extent, age correlated positively 
with increasing psychopathology (Table 3). 
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TABLE 3. RELATIONS~P AMONG SCHIZOPHRENICS BETWEEN PSYCHIATRIC RATING FACTORS, AGE AND 
HOSPITALIZATION, URINE VOLUME AND URINARY CREATININE 
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* Pearson correlation coefficient. 
t Probability of the correlation; NS signilies not significant. 
The most reasonable remaining explanation of these findings is that 5-hydroxyindoleacetic 
acid reflects physical changes resulting from or accompanying psychopathology. Thus, and 
in agreement with the findings of BERLET et al. 26, 24 h creatinine excretion correlated with 
5-hydroxyindoleacetic acid excretion (r = +0*588; N = 61; P <O.OOl), as did 24 h urine 
volume (r = +0*399; P <O=OOl), 24 h urinary sodium (r = +0*506; P <O.OOl), and 24 h 
urinary potassium excretion (r = $0.404; P t0.001). Further, these latter variables also 
generally correlated with psychiatric items in the direction of decreasing values with 
increasing psychopathology (Table 3), the opposite direction from that reported by BERLET 
et al.26 As anticipated, creatinine excretion, in this study, correlated positively for both 
schizophrenics and nonschizophrenics with such anthropometric measures as body weight, 
calf girth and lean body weight. Hospitalization, however, correlated negatively with the 
creatinine excretion of schizophrenics and positively with excretion by nonschizophrenics. 
A possible interpretation is that this reflects a gradual physical deterioration among 
schizophrenics during chronic hospitalization, in contrast to a physical restoration among 
nonschizophrenics, particularly sociopaths, during their shorter hospitalization. Chronic 
schizophrenic psychopathology, then, would be accompanied by a continued loss of 
muscle mass, reflected in decreased creatinine excretion, and decreased 5-hydroxyindoleacetic 
acid excretion. Transitory exacerbations of psychopathology superimposed on this basic 
pattern could temporarily hasten this degenerative process, increasing creatinine excretion 
during rapid loss of muscle mass, as suggested by BERLET et al., and concommitantly 
heighten excretion of Shydroxyindoleacetic acid. This interpretation, while reconciling 
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these apparently discrepant findings, also suggests that 5-hydroxyindoleacetic acid excretion 
is more closely related to physical state than to psychopathology: however, a direct relation- 
ship between psychopathology and indole excretion is not excluded particularly since 
5-hydroxyindoleacetic acid is considered a less sensitive indication of behavioral change 
than is tryptamine or indole3-acetic acid. 
SUMMARY 
Schizophrenics and nonschizophrenics do not differ in urinary excretion of 5-bydroxy- 
indoleacetic acid on either a concentration or 24 h basis, nor do they differ in variability of 
excretion. Although a pattern was observed of decreasing psychopathology with increasing 
5-hydroxyindoleacetic acid excretion, this pattern may be related to alterations in physical 

















WOOLLEY, D. W. and SHAW, E. A biochemical and pharmacological suggestion about certain mental 
disorders. Science 119, 587, 1954. 
GADDUM, J. H. Drugs antagonistic to 5-hydroxytryptamine. Ciba Foundation Symposium on Hyper- 
tension, p. 75, Little, Brown and Co., Boston, 1954. 
BANEWEE, S. and AGARWA~, P. S. Tryptophan-nicotinic acid metabolism in schizophrenia. Proc. 
Sot. exp. Biol. Med. 97, 657, 1958. 
MASUDA, M., SLONECKER, J. S. and DORPAT, T. L. Urinary aromatic metabolites in schizophrenia. 
J. nerv. ment. Dis. 130, 125, 1960. 
VILL~R PP;LAS~, V. and SOLDUGA, J. Metabolites de la serotonine et diagnostique differentiel. 5th 
International Congress of Biochemistry, Vol. 9, p. 418, Abstract # 16.79, Pergamon Press, Oxford, 
1961. 
LEYTON, G. B. Indolic compounds in the urine of schizophrenics. Br. med. J. 2, 1136, 1958. 
BUSCAINO, G. A. and STEFANACHI, L. Metabolism of indoleic substances, especially 5-hydroxyindole- 
acetic acid, in schizophrenia. Confnia neural. 18, 188, 1958. 
BUSCA~NO, G. A. and STEFANACHI, L. Urinary excretion of 5-hydroxyindoleacetic acid in psychotic 
and normal subjects excretion after parenteral administration of serotonin. A.M.A. Archs Neural. 
Psychiatry 80,18, 1958. 
FELDSTEW, A., HOAGLAND, H. and FREEMAN, H. Blood and urinary serotonin and fi-hydroxyindole- 
acetic acid levels in schizophrenic patients and normal subjects. J. nerv. ment. Dis. 129, 62, 1959. 
FELDSTEIN, A., HOAGLAND, H. and FREEMEN, H. On the relationship of serotonin to schizophrenia. 
Science 128, 358, 1958. 
IQ~IZRBACK, B. J., SJOERDSMA, A. and TERRY, L. L. Urinary excretion of the serotonin metabolite, 
5-hydroxyindoleacetic acid, in various clinical conditions. New Engl. J. Med. 255, 270, 1956. 
REIGELHALJPT, L. M. Investigation of urinary excretion patterns in psychiatric subjects. J. nerv. ment. 
Dis. 127, 22, 1958. 
ROBMS. E., Lows, I. P. and HAVNER, N. M. The urinary excretion of 5-hydroxy-3-indoleacetic acid 
(HIAA in patients with schizophrenia and in control subjects. Clin. Res. Proc. 4, 149, 1956. 
SANO, I., KAKIMOTQ Y., OKAMOTO, T., NAKAJIMA, H. and Kuoo, Y. 5-Hydroxyindoleacetic acid 
excretion in urine of schizophrenics with reference to effects of chlorpromazine and reserpine on 
serotonin metabolism. Schwkz med. Wschr. 87, 214, 1957. 
BRUNE, G. G. and HIMWICH, H. E. Biphasic action of reserpine and isocarboxazid and serotonin 
metabolism. Science 133, 190, 1961. 
PSYCHOPATHOLOGY AND 5-HYDROXYINDoLEACETIC A ID EXCRETION 131 
16. 
17. BERLET, H. H.,&JLL, C., IBMWICH, H. E., KOHL, H., MATSOMOTO, K., PSCHEIDT, G. R., SPAIDE, J., 
TOORLENTZ, T. T. and VALVERDE, J. M. Endogenous metabolic factor in schizophrenic behavior. 





BRUNE, G. G. and HIM~ICH, H. E. Biogenic amines and behavior in schizophrenic patients. Recent 
Advances in Biological Psychiatry, J. Wortis (Editor), p. 144, Vol. 5, Plenum Press, New York, 1963. 
GERARD, R. W., et al. The nosology of schizophrenia. Am. J. Psychiut. 120, 16, 1963. 
GERARD, R. W. Nosology of schizophrenia: a co-operative study, Behavl. Sci. 9, 311, 1964. 
LORR, M. Multidimensional scale for rating psychiatric patients. Veterans Administration Technical 
Bulletin TB 10-5-7, Nov. 1953. 




UDENFRIEND, S., TITUS, E. and WEISSBACH, H. The idemification of 5-hydroxy-3-indoleacetic acid in 




BRUNE, G. G. and PSCHEDDT, G. R. Correlations between behavior and urinary excretion of indole 
amines and catecholamines in schizophrenic patients as affected by drugs. Fedn Proc. Fedn Am. 
Sots. exp. Biol. 20, 889, 1961. 
CLARK, L. C., JR. and THOMPSON, H. L.-Determination of &eat&e and creatinine in urine. AnaZyt. 
Chem. 21, 1218, 1949. 
BRUNE, G. G. and HIMWICH, H. E. Indole metabolites in schizophrenic patients. Urinary excretion. 
Archs. gen. Psychiat. 6, 324, 1962. 
BERLET, H. H., PSCHEIDT, G. R., SPAIDE, J. K. and H~MWICH, H. E. Variations of urinary creatinine 
and its correlation to tryptamine excretion in schizophrenic patients. Nature, Lond. 203,1198, 1964. 
